Results for valsartana translation from Slovenian to English

ena kapsula vsebuje 40 mg valsartana.
each capsule contains 40 mg valsartan.

10 mg amlodipina in 160 mg valsartana).
10 mg amlodipine and 160 mg valsartan).

razpolovni čas valsartana je približno 6 ur.
the half-life of valsartan is 6 hours.

linearnost farmakokinetiki amlodipina in valsartana sta linearni.
linearity amlodipine and valsartan exhibit linear pharmacokinetics.

farmakokinetike amlodipina, valsartana in hidroklorotiazida so linearne.
amlodipine, valsartan and hydrochlorothiazide exhibit linear pharmacokinetics.

ena filmsko obložena tableta vsebuje 80 mg valsartana.
each film-coated tablet contains 80 mg valsartan.

ena tableta vsebuje 10 mg amlodipina in 160 mg valsartana.
each tablet contains 10 mg amlodipine and 160 mg valsartan.

ni podatkov o uporabi valsartana in/ali amlodipina med dojenjem.
no information is available regarding the use of valsartan and/or amlodipine during breast-feeding.

ena filmsko obložena tableta vsebuje 5 mg amlodipina in 80 mg valsartana.
each tablet contains 5 mg amlodipine and 80 mg valsartan.

neželeni učinki amlodipina ali valsartana samega, ki so lahko resni:
side effects with amlodipine or valsartan alone which can be serious:

66 neželeni učinki amlodipina ali valsartana samega, ki so lahko resni:
66 if any of these affect you severely, tell your doctor.

nenadni prekinitvi valsartana niso sledili preobratna hipertenzija ali drugi neželeni klinični učinki.
abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events.

povprečni navidezni volumen porazdelitve valsartana znaša 75 litrov, sakubitrila pa 103 litre.
the average apparent volume of distribution of valsartan and sacubitril were 75 litres to 103 litres, respectively.

nenadna prekinitev jemanja amlodipina/valsartana ni povezana s hitrim zvišanjem krvnega tlaka.
abrupt withdrawal of amlodipine/valsartan has not been associated with a rapid increase in blood pressure.

v plazmi so ugotovili majhno koncentracijo hidroksipresnovka (manj kot 10 % auc valsartana).
a hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan auc).

ena tableta vsebuje 10 mg amlodipina (v obliki amlodipinijevega besilata) in 160 mg valsartana.
each tablet contains 10 mg amlodipine (as amlodipine besylate) and 160 mg valsartan.

peroralna absolutna biološka uporabnost sakubitrila je ocenjena na več kot 60 %, valsartana pa na 23 %.
the oral absolute bioavailability of sacubitril and valsartan is estimated to be more than 60% and 23%, respectively.

hitrost in obseg absorpcije amlodipina/valsartana sta enakovredna biološki uporabnosti valsartana in amlodipina, uporabljenih v ločenih tabletah.
the rate and extent of absorption of amlodipine/valsartan are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets.

farmakokinetika zdravila entresto (sakubitrila, substance lbq657 in valsartana) je pri moških in ženskah približno enaka.
the pharmacokinetics of entresto (sacubitril, lbq657 and valsartan) are similar between male and female subjects.

pri bolnikih s hudo okvaro jeter je kominacija amlodipina/valsartana kontraindicirana (glejte poglavje 4.3).
amlodipine/valsartan is contraindicated in patients with severe hepatic impairment (see section 4.3).